2024
Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.
AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B. Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 260-265. PMID: 38841910, PMCID: PMC11379256, DOI: 10.4103/sjg.sjg_19_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseGI fellowsElderly/frail patientsAssociated with higher confidenceExternal rotationInflammatory bowel disease knowledgePreventive health servicesMulticenter survey studyManagement of inflammatory bowel diseaseInflammatory bowel disease managementGastroenterology fellowsHealth servicesSaudi ArabiaFellows' confidenceDidactic sessionsMethods of trainingExtraintestinal manifestationsCounseling patientsIBD patientsBowel diseaseIBD managementPatientsPreference learning methodLow confidenceConfidenceClinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske H, Ward C, Shah S, Holubar S, Al-Bawardy B, Barnes E, Binion D, Bohm M, Brand M, Clarke K, Cohen B, Cross R, Dueker J, Engels M, Farraye F, Fine S, Forster E, Gaidos J, Ginsburg P, Goyal A, Hanson J, Herfath H, Hull T, Kelly C, Lazarev M, Levy L, Melia J, Philpott J, Qazi T, Siegel C, Watson A, Wexner S, Williams E, Regueiro M. Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE. Crohn's & Colitis 360 2024, 6: otae022. PMID: 38720935, PMCID: PMC11078036, DOI: 10.1093/crocol/otae022.Peer-Reviewed Original ResearchInflammatory bowel diseaseReview of patient historyPresentation of inflammatory bowel diseaseInflammatory bowel disease patientsTreated with biologicsCost of patient careClinical management implicationsReassessment of treatmentIBD specialistsClinical responseMedication-inducedIBD patientsPrescribed steroidsPatient careEndoscopic biopsyTherapeutic workupMultidisciplinary managementIBD casesBalloon enteroscopyAdverse eventsDifferential diagnosisDisease mimicsDiverse presentationsPatient historyBowel diseaseEpstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia
Al-Bawardy B, Alfadley A, Almousallam M, AlShathri S, Aboueissa M, Alsulaiman A, Attamimi M, AlMutairdi A. Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 168-172. PMID: 38358251, PMCID: PMC11198918, DOI: 10.4103/sjg.sjg_380_23.Peer-Reviewed Original ResearchSeroprevalence of EBVEpstein-Barr virusInflammatory bowel diseaseYears of ageEBV seroprevalenceEpstein-Barr virus statusCohort of IBD patientsDiagnosis of inflammatory bowel diseaseInflammatory bowel disease patientsRetrospective chart reviewFollow-up timeRate of seroconversionNon-exposureEBV seroconversionThiopurine therapyEBV-seropositiveNegative patientsTertiary centerIBD patientsPrimary outcomeSecondary outcomesBowel diseasePatientsVirus seroprevalenceDisease patients
2023
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssays
2022
Effect of obesity on vedolizumab response in inflammatory bowel disease
Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.Peer-Reviewed Original ResearchBody mass indexInflammatory bowel diseaseSteroid-free clinical remissionNon-obese groupC-reactive proteinObese groupCRP normalizationEndoscopic remissionIBD patientsBowel diseaseDose escalationNormal serum C-reactive proteinMedian body mass indexSerum C-reactive proteinHigher body mass indexEndoscopic remission ratesEffect of obesityVedolizumab discontinuationVedolizumab levelsClinical remissionMedian followRemission rateSecondary outcomesMedian agePrimary outcome
2021
The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services
Hussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services. Crohn's & Colitis 360 2021, 3: otab067. PMID: 36777277, PMCID: PMC9802036, DOI: 10.1093/crocol/otab067.Peer-Reviewed Original ResearchInflammatory bowel diseaseClinic BIBD clinicHerpes zosterClinic AVaccination servicesSite vaccinationVaccine discussionsInflammatory bowel disease clinicHepatitis B vaccinationVaccine-preventable diseasesLow vaccination ratesCompletion ratesB vaccinationIBD patientsIBD physiciansVaccine completionBowel diseaseDisease clinicClinic 1Retrospective studyVaccination ratesDiscussion rateComprehensive careImmunization rates
2018
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado FJ, Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2018, 25: 1072-1079. PMID: 30476314, DOI: 10.1093/ibd/izy341.Peer-Reviewed Original ResearchConceptsBiomechanical CT analysisBone mineral densityHigh fracture riskHigh-risk groupFracture riskCT enterographyIBD patientsFemoral neck bone mineral densityInflammatory bowel disease patientsNeck bone mineral densityWorld Health Organization classificationConsecutive IBD patientsFracture risk classificationBowel disease patientsFindings of CTMetabolic bone diseaseRetrospective reviewClinical featuresExact prevalenceDisease patientsOrganization classificationMineral densityBone diseasePatientsClinical practiceVedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018, 24: 2272-2277. PMID: 29718223, DOI: 10.1093/ibd/izy133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiological TherapyColitis, UlcerativeCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrognosisProspective StudiesRetrospective StudiesTreatment OutcomeTuberculin TestConceptsLatent tuberculosis infectionInflammatory bowel diseaseTuberculin skin testBiologic therapyLTBI treatmentIBD patientsTuberculosis reactivationBowel diseaseTuberculosis infectionLTBI treatment regimenReactivation of TBRisk of reactivationInterferon-gamma releaseOutcome of treatmentStudy inclusion criteriaMedian annual riskAdalimumab monotherapyIsoniazid therapyTB reactivationCertolizumab pegolPrimary outcomeRetrospective reviewTreatment regimenMedian timeGamma release